Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00277810 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
NCT00277810 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 250 participants.
The verdict
NCT00277810, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the safety, tolerability, and efficacy of 3 doses of lecozotan in combination with a cholinesterase inhibitor in patients with mild to moderate Alzheimer's disease (AD).
Interventions
- DRUG lecozotan SR (SRA-333)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2006-03 |
| Est. Completion | 2008-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00277810
The ClinicalTrials.gov registry entry for NCT00277810 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which lecozotan SR (SRA-333) is the first listed.
NCT00277810 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00277810 about?
NCT00277810 is a clinical study titled "Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease". The purpose of the study is to determine the safety, tolerability, and efficacy of 3 doses of lecozotan in combination with a cholinesterase inhibitor in patients with mild to moderate Alzheimer's disease (AD).
What is the current status of trial NCT00277810?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2006-03. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00277810?
The interventions under investigation include: lecozotan SR (SRA-333) (DRUG).
Who is sponsoring clinical trial NCT00277810?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.